Akira A. Shishido
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Akira A. Shishido has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
Alexander Vostal
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
2 shared publications- Daisuke Yoneoka
Department of Epidemiology, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan
2 shared publications - Hiroyoshi Toyoshiba
FRONTEO Healthcare, Inc. Japan, Tokyo, JP
2 shared publications - Hisashi Noma
The Graduate Institute for Advanced Studies , The Graduate University for Advanced Studies , Tokyo , Japan
2 shared publications Kapil Saharia
Division of Infectious Diseases, University of Maryland Medical Center, Baltimore, USA
2 shared publications- Kimihiro Hino
FRONTEO Healthcare, Inc. Japan, Tokyo, JP
2 shared publications
Latest Publications
- 28 July 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (2) , e218290
Teaching NeuroImage: Diffuse Cerebellar Involvement With Obstructive Hydrocephalus in Powassan Virus Encephalitis
- 28 July 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (2) , e218290
Teaching NeuroImage: Diffuse Cerebellar Involvement With Obstructive Hydrocephalus in Powassan Virus Encephalitis
- 15 June 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (6) , 1091-1095
Fever in a Man with Uncontrolled HIV
- 15 June 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 82 (6) , 1091-1095
Fever in a Man with Uncontrolled HIV
- 1 January 2026
- Published by Breakaway Media, LLC in Journal of Special Operations Medicine
- Vol. 26 (3) , 80
Melioidosis: A Review and Update for the Special Operations Provider
Melioidosis: A Review and Update for the Special Operations Provider Goldberg C, Shishido AA Ahead of Print. Publication Type: Journal Article Melioidosis, caused by the gram-negative bacillus Burkholderia pseudomallei – a Tier 1 Select Biological agent – remains a significant cause of severe community-acquired infection in tropical regions, but with recent expanding recognition in […] Melioidosis: A Review and Update for the Special Operations Provider Goldberg C, Shishido AA Ahead of Print. Publication Type: Journal Article Melioidosis, caused by the gram-negative bacillus Burkholderia pseudomallei – a Tier 1 Select Biological agent – remains a significant cause of severe community-acquired infection in tropical regions, but with recent expanding recognition in […]
- 1 January 2026
- Published by Breakaway Media, LLC in Journal of Special Operations Medicine
- Vol. 26 (3) , 80
Melioidosis: A Review and Update for the Special Operations Provider
Melioidosis: A Review and Update for the Special Operations Provider Goldberg C, Shishido AA Ahead of Print. Publication Type: Journal Article Melioidosis, caused by the gram-negative bacillus Burkholderia pseudomallei – a Tier 1 Select Biological agent – remains a significant cause of severe community-acquired infection in tropical regions, but with recent expanding recognition in […] Melioidosis: A Review and Update for the Special Operations Provider Goldberg C, Shishido AA Ahead of Print. Publication Type: Journal Article Melioidosis, caused by the gram-negative bacillus Burkholderia pseudomallei – a Tier 1 Select Biological agent – remains a significant cause of severe community-acquired infection in tropical regions, but with recent expanding recognition in […]
- Open Access
- 30 July 2025
- Published by SAGE Publications in Surgical Infections
- Vol. 26 (6) , 384-389
Hyperbaric Oxygen Therapy for Necrotizing Soft Tissue Infections: A Retrospective Cohort Analysis of Clinical Outcomes
Background: Hyperbaric oxygen therapy (HBOT) is an adjunctive therapy for necrotizing soft tissue infections (NSTIs) that remains controversial due to lack of quality clinical evidence. This retrospective cohort examines the impact of HBOT on clinical outcomes from NSTI at a single center where evaluation for HBOT is standard of care. Methods: The COVID-19 pandemic disrupted HBOT service and NSTI cases went without HBOT treatment, allowing for a comparison of treatment groups. The clinical outcomes of 253 patients with NSTI that were evaluated for HBOT were compared; 143 (56.3%) received HBOT and 110 (43.3%) did not. Results: Baseline characteristics were similar except for surface area of the wounds and distribution on the extremities. More patients in the non-HBOT group died within 90 days of admission than those in the HBOT group (5.8% vs. 15.4%, p = 0.015). Further, patients with large wounds (≥450 cm 2 ) and those with high APACHE II scores (≥18) who underwent HBOT had significantly lower risk of death than patients who did not (odds ratio [OR] 0.12, 95% confidence interval [CI] 0.02–0.72). Conclusion: Our study shows that there was a mortality benefit in patients with NSTI that was more significant in patients with large wounds and higher APACHE II scores.
- 30 July 2025
- Published by SAGE Publications in Surgical Infections
- Vol. 26 (6) , 384-389
Open AccessHyperbaric Oxygen Therapy for Necrotizing Soft Tissue Infections: A Retrospective Cohort Analysis of Clinical Outcomes
Background: Hyperbaric oxygen therapy (HBOT) is an adjunctive therapy for necrotizing soft tissue infections (NSTIs) that remains controversial due to lack of quality clinical evidence. This retrospective cohort examines the impact of HBOT on clinical outcomes from NSTI at a single center where evaluation for HBOT is standard of care. Methods: The COVID-19 pandemic disrupted HBOT service and NSTI cases went without HBOT treatment, allowing for a comparison of treatment groups. The clinical outcomes of 253 patients with NSTI that were evaluated for HBOT were compared; 143 (56.3%) received HBOT and 110 (43.3%) did not. Results: Baseline characteristics were similar except for surface area of the wounds and distribution on the extremities. More patients in the non-HBOT group died within 90 days of admission than those in the HBOT group (5.8% vs. 15.4%, p = 0.015). Further, patients with large wounds (≥450 cm 2 ) and those with high APACHE II scores (≥18) who underwent HBOT had significantly lower risk of death than patients who did not (odds ratio [OR] 0.12, 95% confidence interval [CI] 0.02–0.72). Conclusion: Our study shows that there was a mortality benefit in patients with NSTI that was more significant in patients with large wounds and higher APACHE II scores.
- Open Access
- 21 July 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (8) , ofaf430
A Review of Alpha-Gal Syndrome for the Infectious Diseases Practitioner
Alpha-gal syndrome (AGS) is an emerging allergic disease caused by an immunoglobulin E (IgE) response to galactose-α-1,3-galactose (alpha-gal), a sugar found in mammalian meat. The initial IgE sensitization follows a bite from the Amblyomma americanum (lone star) tick in the United States, although other tick species can also cause the disease. AGS presents with delayed symptoms, primarily gastrointestinal or allergic reactions like urticaria or anaphylaxis, hours after mammalian meat consumption. The nonspecificity of the symptoms can delay the diagnosis of AGS for years. Diagnosis relies on clinical evaluation and detection of alpha-gal–specific IgE in blood. As the lone star tick's range is expanding beyond the southern United States, AGS is gaining recognition in other regions. However, many healthcare providers remain unaware of the condition, leading to misdiagnosis. Infectious diseases physicians who frequently evaluate patients with tick exposure must be familiar with AGS, including tick identification, bite prevention, and knowledge of the alpha-gal–containing vaccines.
- 21 July 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (8) , ofaf430
Open AccessA Review of Alpha-Gal Syndrome for the Infectious Diseases Practitioner
Alpha-gal syndrome (AGS) is an emerging allergic disease caused by an immunoglobulin E (IgE) response to galactose-α-1,3-galactose (alpha-gal), a sugar found in mammalian meat. The initial IgE sensitization follows a bite from the Amblyomma americanum (lone star) tick in the United States, although other tick species can also cause the disease. AGS presents with delayed symptoms, primarily gastrointestinal or allergic reactions like urticaria or anaphylaxis, hours after mammalian meat consumption. The nonspecificity of the symptoms can delay the diagnosis of AGS for years. Diagnosis relies on clinical evaluation and detection of alpha-gal–specific IgE in blood. As the lone star tick's range is expanding beyond the southern United States, AGS is gaining recognition in other regions. However, many healthcare providers remain unaware of the condition, leading to misdiagnosis. Infectious diseases physicians who frequently evaluate patients with tick exposure must be familiar with AGS, including tick identification, bite prevention, and knowledge of the alpha-gal–containing vaccines.
- Open Access
- 11 December 2023
- Published by Wiley in Journal of Medical Virology
- Vol. 95 (12) , e29277
Optimal management of severe mpox in patients with uncontrolled human immunodeficiency virus
In May 2022, a cluster of nontravel‐related cases of human mpox were reported in the United Kingdom. The outbreak has since spread worldwide infecting over 85 000 patients and causing over 100 deaths. Recent data clearly suggest that patients infected with human immunodeficiency virus (HIV) with CD4 counts less than 200 cells per mm3 suffer significantly worse outcomes than immunocompetent patients. The available countermeasures lack robust clinical data and are deployed based on in vitro and animal studies as well as extrapolations from use against other poxviruses. In many cases, despite administration of these available treatments, initiation of antiretroviral therapy (ART), and management of suspected immune reconstitution inflammatory syndrome after initiating ART, patients die. This review summarizes available data, identifies knowledge gaps and proposes recommendations on the management of severe mpox in people living with HIV.
- 11 December 2023
- Published by Wiley in Journal of Medical Virology
- Vol. 95 (12) , e29277
Open AccessOptimal management of severe mpox in patients with uncontrolled human immunodeficiency virus
In May 2022, a cluster of nontravel‐related cases of human mpox were reported in the United Kingdom. The outbreak has since spread worldwide infecting over 85 000 patients and causing over 100 deaths. Recent data clearly suggest that patients infected with human immunodeficiency virus (HIV) with CD4 counts less than 200 cells per mm3 suffer significantly worse outcomes than immunocompetent patients. The available countermeasures lack robust clinical data and are deployed based on in vitro and animal studies as well as extrapolations from use against other poxviruses. In many cases, despite administration of these available treatments, initiation of antiretroviral therapy (ART), and management of suspected immune reconstitution inflammatory syndrome after initiating ART, patients die. This review summarizes available data, identifies knowledge gaps and proposes recommendations on the management of severe mpox in people living with HIV.
- Open Access
- 21 September 2023
- Published by Wiley
Optimal Management of Severe Mpox in Patients with Uncontrolled HIV
In May 2022, a cluster of non-travel-related cases of human mpox were reported in the UK. The outbreak has since spread world-wide infecting over 85,000 patients and causing over 100 deaths. Recent data clearly suggest that patients infected with Human Immunodeficiency Virus (HIV) with CD4 counts less than 200 cells per mm 3 suffer significantly worse outcomes than immunocompetent patients. The available countermeasures lack robust clinical data and are deployed based on in vitro and animal studies as well as extrapolations from use against other poxviruses. In many cases, despite administration of these available treatments, initiation of antiretroviral therapy, and management of Immune Reconstitution Inflammatory Syndrome (IRIS), patients die. This review summarizes available data, identifies knowledge gaps and proposes recommendations on the management of severe mpox in PLWH.
- 21 September 2023
- Published by Wiley
Open AccessOptimal Management of Severe Mpox in Patients with Uncontrolled HIV
In May 2022, a cluster of non-travel-related cases of human mpox were reported in the UK. The outbreak has since spread world-wide infecting over 85,000 patients and causing over 100 deaths. Recent data clearly suggest that patients infected with Human Immunodeficiency Virus (HIV) with CD4 counts less than 200 cells per mm 3 suffer significantly worse outcomes than immunocompetent patients. The available countermeasures lack robust clinical data and are deployed based on in vitro and animal studies as well as extrapolations from use against other poxviruses. In many cases, despite administration of these available treatments, initiation of antiretroviral therapy, and management of Immune Reconstitution Inflammatory Syndrome (IRIS), patients die. This review summarizes available data, identifies knowledge gaps and proposes recommendations on the management of severe mpox in PLWH.
- 1 December 2022
- Published by Springer Nature in Current Treatment Options in Infectious Diseases
- Vol. 14 (4) , 43-66
Mpox: Special Considerations in the Immunocompromised Host
- 1 December 2022
- Published by Springer Nature in Current Treatment Options in Infectious Diseases
- Vol. 14 (4) , 43-66
Mpox: Special Considerations in the Immunocompromised Host
- Open Access
- 20 September 2022
- Published by Medical Journals Sweden AB in Acta Orthopaedica
- Vol. 93, 756-759
Salphage: salvage bacteriophage therapy for a recalcitrant Klebsiella pneumoniae prosthetic shoulder infection — a case report
- 20 September 2022
- Published by Medical Journals Sweden AB in Acta Orthopaedica
- Vol. 93, 756-759
Open AccessSalphage: salvage bacteriophage therapy for a recalcitrant Klebsiella pneumoniae prosthetic shoulder infection — a case report
- Open Access
- 1 May 2022
- Published by American College of Physicians in Annals of Internal Medicine: Clinical Cases
- Vol. 1 (3)
A Case of Steroid-Responsive Multisystem Inflammatory Syndrome in Adults With SARS-CoV-2
While the COVID-19 pandemic continues to evolve, different phenotypic variants of the disease are being recognized. Multisystem inflammatory syndrome in adults is an emerging entity that has yet to...
- 1 May 2022
- Published by American College of Physicians in Annals of Internal Medicine: Clinical Cases
- Vol. 1 (3)
Open AccessA Case of Steroid-Responsive Multisystem Inflammatory Syndrome in Adults With SARS-CoV-2
While the COVID-19 pandemic continues to evolve, different phenotypic variants of the disease are being recognized. Multisystem inflammatory syndrome in adults is an emerging entity that has yet to...